0R15 8884.0068 1.4156% 0R1E 9171.0 0.0% 0M69 None None% 0R2V 255.5 0.0% 0QYR 1619.0 0.0% 0QYP 434.5 0.0% 0RUK None None% 0RYA 1606.0 4.9673% 0RIH 195.2 1.3763% 0RIH 195.2 0.0% 0R1O 225.5 9900.0% 0R1O None None% 0QFP None None% 0M2Z 255.0 0.2457% 0VSO 33.3 -6.4738% 0R1I None None% 0QZI 604.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 246.8 2.9706%
Last update at 2024-12-26T18:53:00Z
| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Income before tax | -250.46100M | -41.83900M |
| Minority interest | - | - |
| Net income | -250.46100M | -41.83900M |
| Selling general administrative | 24.05M | 3.56M |
| Selling and marketing expenses | - | - |
| Gross profit | - | - |
| Reconciled depreciation | - | - |
| Ebit | -254.68100M | -41.79400M |
| Ebitda | -254.86300M | -41.79400M |
| Depreciation and amortization | -0.18200M | - |
| Non operating income net other | - | - |
| Operating income | -254.68100M | -41.79400M |
| Other operating expenses | 254.68M | 41.79M |
| Interest expense | - | - |
| Tax provision | - | - |
| Interest income | 4.17M | - |
| Net interest income | 4.17M | - |
| Extraordinary items | - | - |
| Non recurring | - | - |
| Other items | - | - |
| Income tax expense | -4.17000M | - |
| Total revenue | 0.00000M | 0.00000M |
| Total operating expenses | 254.68M | 41.79M |
| Cost of revenue | - | - |
| Total other income expense net | 0.05M | -0.04500M |
| Discontinued operations | - | - |
| Net income from continuing ops | -250.46100M | -41.83900M |
| Net income applicable to common shares | -64.77200M | -41.83900M |
| Preferred stock and other adjustments | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 742.69M | 332.96M | 102.30M |
| Intangible assets | - | - | - |
| Earning assets | - | - | - |
| Other current assets | 1.71M | 4.16M | 0.06M |
| Total liab | 86.35M | 444.35M | 144.36M |
| Total stockholder equity | 656.34M | -111.39100M | -42.05600M |
| Deferred long term liab | - | 1.90M | - |
| Other current liab | 43.24M | 25.55M | 10.61M |
| Common stock | 0.00100M | - | - |
| Capital stock | 0.00100M | 0.00000M | 0.00000M |
| Retained earnings | -488.71900M | -250.11100M | -42.30600M |
| Other liab | - | 10.29M | - |
| Good will | - | - | - |
| Other assets | - | 3.86M | - |
| Cash | 218.10M | 278.56M | 102.24M |
| Cash and equivalents | - | - | - |
| Total current liabilities | 85.16M | 32.83M | 11.74M |
| Current deferred revenue | - | - | - |
| Net debt | -216.90300M | -278.55600M | -102.24200M |
| Short term debt | - | - | - |
| Short long term debt | - | - | - |
| Short long term debt total | 1.19M | - | - |
| Other stockholder equity | 1144.89M | 138.81M | 0.25M |
| Property plant equipment | - | - | - |
| Total current assets | 736.64M | 330.22M | 102.30M |
| Long term investments | - | - | - |
| Net tangible assets | - | -102.86200M | -42.05600M |
| Short term investments | 503.23M | 47.51M | - |
| Net receivables | 4.75M | 0.39M | - |
| Long term debt | - | - | - |
| Inventory | 8.85M | - | - |
| Accounts payable | 41.92M | 7.28M | 1.13M |
| Total permanent equity | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - |
| Accumulated other comprehensive income | 0.16M | -0.08600M | - |
| Additional paid in capital | - | - | - |
| Common stock total equity | - | - | - |
| Preferred stock total equity | - | - | - |
| Retained earnings total equity | - | - | - |
| Treasury stock | - | - | - |
| Accumulated amortization | - | - | - |
| Non currrent assets other | 2.68M | 2.74M | - |
| Deferred long term asset charges | - | - | - |
| Non current assets total | 6.05M | 2.74M | 0.00000M |
| Capital lease obligations | 1.19M | - | - |
| Long term debt total | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 |
| Investments | -47.87400M | -25.00000M |
| Change to liabilities | 3.78M | 1.12M |
| Total cashflows from investing activities | -47.87400M | -25.00000M |
| Net borrowings | - | - |
| Total cash from financing activities | 274.26M | 124.72M |
| Change to operating activities | -3.84300M | 10.51M |
| Net income | -64.77200M | -41.83900M |
| Change in cash | 164.87M | 94.74M |
| Begin period cash flow | 102.24M | 7.50M |
| End period cash flow | 267.11M | 102.24M |
| Total cash from operating activities | -61.52000M | -4.97900M |
| Issuance of capital stock | 263.97M | 124.70M |
| Depreciation | - | - |
| Other cashflows from investing activities | - | - |
| Dividends paid | - | - |
| Change to inventory | - | - |
| Change to account receivables | - | - |
| Sale purchase of stock | - | - |
| Other cashflows from financing activities | 274.26M | -25.00000M |
| Change to netincome | 3.32M | 25.23M |
| Capital expenditures | 0.00000M | 25.00M |
| Change receivables | - | - |
| Cash flows other operating | - | - |
| Exchange rate changes | - | - |
| Cash and cash equivalents changes | - | - |
| Change in working capital | -0.06700M | 11.63M |
| Stock based compensation | 4.05M | 0.23M |
| Other non cash items | -0.73300M | 25.00M |
| Free cash flow | -61.52000M | -29.97900M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| SLRN ACELYRIN, INC. Common Stock |
0.07 2.21% | 3.24 | - | - | - | 0.80 | 0.46 | |
| NVO Novo Nordisk A/S |
0.48 0.55% | 87.85 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.75 0.86% | 87.75 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.19 0.29% | 409.37 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
0.27 0.04% | 714.74 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
4149 Liberty Canyon Road, Agoura Hills, CA, United States, 91301
| Name | Title | Year Born |
|---|---|---|
| Dr. Shao-Lee Lin M.D., Ph.D. | Co-Founder, CEO & Director | 1968 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | 1978 |
| Mr. Gilbert M. Labrucherie J.D. | Chief Financial Officer, Principal Financial Officer & principal accounting officer | 1972 |
| Ms. Mina Kim | Chief Legal & Administrative Officer | 1974 |
| Mr. Tyler Marciniak | Head of Investor Relations & Communications | NA |
| Mr. Ron Oyston | Chief People Officer | 1970 |
| Dr. Paul M. Peloso M.D., M.Sc. | Chief Medical Officer | 1958 |
| Ms. Suzy Buckhalter CPA | Senior Director of Finance & Accounting | NA |
| Mr. Kenneth A. Lock | Chief Commercial Officer | 1974 |
| Dr. Shephard Mpofu M.D. | Senior Vice President of Development | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...